Solitary fibrous tumor/hemangiopericytoma: Treatment results based on the 2016 WHO classification

Kyoung Su Sung, Ju Hyung Moon, Eui Hyun Kim, Seok Gu Kang, Se Hoon Kim, Chang Ok Suh, Sun Ho Kim, Kyu Sung Lee, Won Seok Chang, Jong Hee Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a new combined entity for which a soft-tissue–type grading system, ranging from grades I to III, has been introduced in the 2016 WHO classification of tumors of the CNS. The results of the treatment of this new disease entity require evaluation. METHODS The authors retrospectively reevaluated the pathological findings and medical records of patients with SFT/ HPC. This study included 60 patients (27 men and 33 women, median age 42.5 years, range 13–69 years) treated at Severance Hospital between February 1981 and February 2016. Four, 40, and 16 patients were categorized as having SFT/HPC grades I, II, and III, respectively. Among these patients, SFTs diagnosed in 7 patients were regraded as grades I (n = 4), II (n = 2), and III (n = 1). RESULTS The median overall survival (OS) was 73.2 months (range 1.4–275.7 months), and the progression-free survival (PFS) after the first operation was 53.8 months (range 1.4–217.7 months). Six patients (10%) showed extracranial metastasis during a median period of 103.7 months (range 31.9–182.3 months). Nineteen patients (31.7%) presented with tumor recurrences. The patients in the grade III group had shorter PFS and OS, as well as a shorter period to extracranial metastasis, compared with patients in the grade II group. In the grade II group, patients who underwent gross-total resection showed longer PFS than those who underwent subtotal resection; however, there was no difference in OS. Patients who underwent adjuvant radiation therapy (RT) after surgery had longer PFS compared with that of patients who did not undergo adjuvant RT. CONCLUSIONS The SFT/HPC grade I group showed a relatively benign course compared with those of the other groups. The grade III group presented a course with a more aggressive nature than that of the grade II group. In the grade II group, the extent of resection and adjuvant RT was significantly associated with longer PFS. The long-term follow-up and periodic systemic evaluation are mandatory to detect systemic metastasis.

Original languageEnglish
Pages (from-to)418-425
Number of pages8
JournalJournal of neurosurgery
Volume130
Issue number2
DOIs
Publication statusPublished - 2019 Feb

Fingerprint

Solitary Fibrous Tumors
Hemangiopericytoma
Disease-Free Survival
Therapeutics
Radiotherapy
Neoplasm Metastasis
Survival
Medical Records

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Sung, Kyoung Su ; Moon, Ju Hyung ; Kim, Eui Hyun ; Kang, Seok Gu ; Kim, Se Hoon ; Suh, Chang Ok ; Kim, Sun Ho ; Lee, Kyu Sung ; Chang, Won Seok ; Chang, Jong Hee. / Solitary fibrous tumor/hemangiopericytoma : Treatment results based on the 2016 WHO classification. In: Journal of neurosurgery. 2019 ; Vol. 130, No. 2. pp. 418-425.
@article{9441343fbc1d43678f7266413b08aeb3,
title = "Solitary fibrous tumor/hemangiopericytoma: Treatment results based on the 2016 WHO classification",
abstract = "OBJECTIVE Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a new combined entity for which a soft-tissue–type grading system, ranging from grades I to III, has been introduced in the 2016 WHO classification of tumors of the CNS. The results of the treatment of this new disease entity require evaluation. METHODS The authors retrospectively reevaluated the pathological findings and medical records of patients with SFT/ HPC. This study included 60 patients (27 men and 33 women, median age 42.5 years, range 13–69 years) treated at Severance Hospital between February 1981 and February 2016. Four, 40, and 16 patients were categorized as having SFT/HPC grades I, II, and III, respectively. Among these patients, SFTs diagnosed in 7 patients were regraded as grades I (n = 4), II (n = 2), and III (n = 1). RESULTS The median overall survival (OS) was 73.2 months (range 1.4–275.7 months), and the progression-free survival (PFS) after the first operation was 53.8 months (range 1.4–217.7 months). Six patients (10{\%}) showed extracranial metastasis during a median period of 103.7 months (range 31.9–182.3 months). Nineteen patients (31.7{\%}) presented with tumor recurrences. The patients in the grade III group had shorter PFS and OS, as well as a shorter period to extracranial metastasis, compared with patients in the grade II group. In the grade II group, patients who underwent gross-total resection showed longer PFS than those who underwent subtotal resection; however, there was no difference in OS. Patients who underwent adjuvant radiation therapy (RT) after surgery had longer PFS compared with that of patients who did not undergo adjuvant RT. CONCLUSIONS The SFT/HPC grade I group showed a relatively benign course compared with those of the other groups. The grade III group presented a course with a more aggressive nature than that of the grade II group. In the grade II group, the extent of resection and adjuvant RT was significantly associated with longer PFS. The long-term follow-up and periodic systemic evaluation are mandatory to detect systemic metastasis.",
author = "Sung, {Kyoung Su} and Moon, {Ju Hyung} and Kim, {Eui Hyun} and Kang, {Seok Gu} and Kim, {Se Hoon} and Suh, {Chang Ok} and Kim, {Sun Ho} and Lee, {Kyu Sung} and Chang, {Won Seok} and Chang, {Jong Hee}",
year = "2019",
month = "2",
doi = "10.3171/2017.9.JNS171057",
language = "English",
volume = "130",
pages = "418--425",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

Solitary fibrous tumor/hemangiopericytoma : Treatment results based on the 2016 WHO classification. / Sung, Kyoung Su; Moon, Ju Hyung; Kim, Eui Hyun; Kang, Seok Gu; Kim, Se Hoon; Suh, Chang Ok; Kim, Sun Ho; Lee, Kyu Sung; Chang, Won Seok; Chang, Jong Hee.

In: Journal of neurosurgery, Vol. 130, No. 2, 02.2019, p. 418-425.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Solitary fibrous tumor/hemangiopericytoma

T2 - Treatment results based on the 2016 WHO classification

AU - Sung, Kyoung Su

AU - Moon, Ju Hyung

AU - Kim, Eui Hyun

AU - Kang, Seok Gu

AU - Kim, Se Hoon

AU - Suh, Chang Ok

AU - Kim, Sun Ho

AU - Lee, Kyu Sung

AU - Chang, Won Seok

AU - Chang, Jong Hee

PY - 2019/2

Y1 - 2019/2

N2 - OBJECTIVE Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a new combined entity for which a soft-tissue–type grading system, ranging from grades I to III, has been introduced in the 2016 WHO classification of tumors of the CNS. The results of the treatment of this new disease entity require evaluation. METHODS The authors retrospectively reevaluated the pathological findings and medical records of patients with SFT/ HPC. This study included 60 patients (27 men and 33 women, median age 42.5 years, range 13–69 years) treated at Severance Hospital between February 1981 and February 2016. Four, 40, and 16 patients were categorized as having SFT/HPC grades I, II, and III, respectively. Among these patients, SFTs diagnosed in 7 patients were regraded as grades I (n = 4), II (n = 2), and III (n = 1). RESULTS The median overall survival (OS) was 73.2 months (range 1.4–275.7 months), and the progression-free survival (PFS) after the first operation was 53.8 months (range 1.4–217.7 months). Six patients (10%) showed extracranial metastasis during a median period of 103.7 months (range 31.9–182.3 months). Nineteen patients (31.7%) presented with tumor recurrences. The patients in the grade III group had shorter PFS and OS, as well as a shorter period to extracranial metastasis, compared with patients in the grade II group. In the grade II group, patients who underwent gross-total resection showed longer PFS than those who underwent subtotal resection; however, there was no difference in OS. Patients who underwent adjuvant radiation therapy (RT) after surgery had longer PFS compared with that of patients who did not undergo adjuvant RT. CONCLUSIONS The SFT/HPC grade I group showed a relatively benign course compared with those of the other groups. The grade III group presented a course with a more aggressive nature than that of the grade II group. In the grade II group, the extent of resection and adjuvant RT was significantly associated with longer PFS. The long-term follow-up and periodic systemic evaluation are mandatory to detect systemic metastasis.

AB - OBJECTIVE Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a new combined entity for which a soft-tissue–type grading system, ranging from grades I to III, has been introduced in the 2016 WHO classification of tumors of the CNS. The results of the treatment of this new disease entity require evaluation. METHODS The authors retrospectively reevaluated the pathological findings and medical records of patients with SFT/ HPC. This study included 60 patients (27 men and 33 women, median age 42.5 years, range 13–69 years) treated at Severance Hospital between February 1981 and February 2016. Four, 40, and 16 patients were categorized as having SFT/HPC grades I, II, and III, respectively. Among these patients, SFTs diagnosed in 7 patients were regraded as grades I (n = 4), II (n = 2), and III (n = 1). RESULTS The median overall survival (OS) was 73.2 months (range 1.4–275.7 months), and the progression-free survival (PFS) after the first operation was 53.8 months (range 1.4–217.7 months). Six patients (10%) showed extracranial metastasis during a median period of 103.7 months (range 31.9–182.3 months). Nineteen patients (31.7%) presented with tumor recurrences. The patients in the grade III group had shorter PFS and OS, as well as a shorter period to extracranial metastasis, compared with patients in the grade II group. In the grade II group, patients who underwent gross-total resection showed longer PFS than those who underwent subtotal resection; however, there was no difference in OS. Patients who underwent adjuvant radiation therapy (RT) after surgery had longer PFS compared with that of patients who did not undergo adjuvant RT. CONCLUSIONS The SFT/HPC grade I group showed a relatively benign course compared with those of the other groups. The grade III group presented a course with a more aggressive nature than that of the grade II group. In the grade II group, the extent of resection and adjuvant RT was significantly associated with longer PFS. The long-term follow-up and periodic systemic evaluation are mandatory to detect systemic metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85064818592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064818592&partnerID=8YFLogxK

U2 - 10.3171/2017.9.JNS171057

DO - 10.3171/2017.9.JNS171057

M3 - Article

AN - SCOPUS:85064818592

VL - 130

SP - 418

EP - 425

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -